Loading page…

Report overview

The report describes UCB's 2011 transformation toward a patient-centric biopharmaceutical company and reports consolidated revenue of €3.246 billion. It highlights the growth and reach of Cimzia, Vimpat, and Neupro, alongside continued investment in research and development. The report also records a year-end workforce of 8,506 and provides CSR performance data on energy, water, emissions, and waste.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2011
Period: Ends 31 December 2011
Language
Pages
File size

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

GRI level

Assurance

Provider
Scope
Statement included
Metrics assured

ESG & Materiality

ESG data

Indicators available in this report:

Energy consumption
Waste
Employees
Women on the board

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services